Clinical Trial Update: Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of vorinostat and Lutetium-177 PSMA-617 for PSMA-low metastatic castration-resistant prostate cancer is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• Pluvicto (Lutetium-177-PSMA-617) (Lutetium-177-PSMA-617)
• Vorinostat (vorinostat)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Status: RECRUITING